Neurocrine Biosciences, Inc. (LON:0K6R)

Market Cap	10.43B
Revenue (ttm)	2.00B
Net Income (ttm)	318.41M
Shares Out	n/a
EPS (ttm)	3.12
PE Ratio	32.76
Forward PE	14.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164
Average Volume	1,231
Open	144.39
Previous Close	144.04
Day's Range	141.29 - 144.39
52-Week Range	84.36 - 161.05
Beta	n/a
RSI	40.27
Earnings Date	Feb 9, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD